Overview

A Safety and Efficacy Trial of a Combination of Bendamustine, Rituximab and Lenalidomide in Patients With Chronic Lymphocytic Leukemia

Status:
Completed

Trial end date:
2015-06-01

Target enrollment:

Participant gender:

Summary

This is a prospective, multicenter, open label, non-randomized, phase I/II-study to define safety and efficacy of BRL combination in relapsed/refractory patients and to recommend a safe and efficacious dose for future phase II/III study. Hypothesis: The simultaneous administration of BRL in relapsed CLL is feasible, safe and efficient.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

German CLL Study Group

Collaborators:

Celgene
Mundipharma Research GmbH & Co KG
Roche Pharma AG

Treatments:

Bendamustine Hydrochloride
Lenalidomide
Rituximab
Thalidomide